Canadian provinces exhibit significant disparities in TURP reimbursement rates, with 20%-30% differences and no alignment with the cost-of-living index. Advanced BPH techniques like Greenlight and ...

Accurate staging and thorough work-up, including urine cytology and CT urography, are crucial for optimal UTUC management. Treatment options for low-grade UTUC include active surveillance, endoscopic ...

Lifestyle modifications, including yoga, hypnosis, and nutraceuticals, are increasingly used in BPH management, reflecting a trend towards integrating alternative medicine with traditional treatments.

Bel-sar is being investigated as an immunoablative agent to potentially replace TURBTs in NMIBC treatment, offering an office-based alternative. Combining bel-sar with cytokine therapies like IL-15 or ...

"If you tapped into your emergency fund for any reason this year, it is important to make sure the account is replenished," writes Jeff Witz, CFP. This year has been a rollercoaster. Inflation finally ...

The LOBSTER study assesses CxBladder tests for urothelial carcinoma recurrence, aiming to enroll 400-500 patients with 75 confirmed tumors. Participants provide urine samples over 2 years, alternating ...

The P-CARE model integrates polygenic scores, family history, and genetic ancestry to stratify prostate cancer risk effectively. High P-CARE scores correlate with increased risk of any, metastatic, ...

68Gallium PSMA-11 PET is preferred for confirming lutetium therapy eligibility due to its high specificity in detecting PSMA expression. Alternatives include 18F-DCFPyL PET, which also targets PSMA, ...

The NRG-GU011 trial investigates relugolix plus SBRT versus SBRT alone in PET-oligometastatic prostate cancer. ORIOLE and STOMP studies indicate SBRT can delay recurrence without early ADT in some ...

Barrigel rectal spacer aims to protect the rectum during radiation therapy for prostate cancer, with FDA clearance for T1-T3b cases. The PPRT trial is the first to include patients with recurrent ...

CMS will separately reimburse diagnostic radiopharmaceuticals exceeding $630 per day, enhancing access to advanced nuclear medicine scans. The new policy, effective January 1, 2025, provides stable ...

The codes will go into effect on January 1, 2026. The panel examines the challenges associated with effectively interpreting and applying biomarker test results in prostate cancer management and ...